Medicare Enrolled
Dr. Robert Moricca, MD
Pulmonary Disease · Newport Beach, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Moricca from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Moricca?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Moricca
Dr. Robert Moricca is a pulmonary disease specialist in Newport Beach, CA, with 19 years of NPI registration. Based on federal Medicare data, Dr. Moricca performed 2,660 Medicare services across 1,430 unique beneficiaries.
Between the years covered by Open Payments, Dr. Moricca received a total of $14,971 from 47 pharmaceutical and/or device companies across 589 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Moricca is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice
▲ Top 14% volume in CA
$14,971 industry payments
Medicare Practice Summary
Medicare Utilization ↗2,660
Medicare services
Top 14% in CA for pulmonary disease
1,430
Unique beneficiaries
$55
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~140 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Airflow rate measurement test A test that measures the rate of airflow. This procedure assesses how quickly air moves. |
768 | $33 | $95 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
752 | $103 | $170 |
| Betamethasone steroid injection An injection containing a combination of betamethasone acetate and betamethasone sodium phosphate. |
416 | $5 | $8 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
104 | $12 | $32 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
72 | $98 | $134 |
| Breathing device use evaluation An assessment of how a patient uses a breathing device. The provider reviews the patient's technique and device handling. |
71 | $15 | $24 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
63 | $52 | $98 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
62 | $49 | $97 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
61 | $34 | $126 |
| Inhalation treatment for airway obstruction or sputum production A treatment involving the inhalation of medication to help clear airway obstructions or reduce sputum production. |
61 | $8 | $60 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
58 | $153 | $235 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
44 | $76 | $126 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
28 | $132 | $380 |
| Nitric oxide gas level test A test that measures the level of nitric oxide gas in the body. |
27 | $18 | $40 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
26 | $65 | $99 |
| New patient office visit, complex (60-74 min) | 22 | $177 | $399 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
13 | $110 | $315 |
| Telephone medical discussion, 5-10 minutes A phone conversation with a physician lasting between 5 and 10 minutes to discuss medical matters. |
12 | $43 | $77 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$14,971
Total received (2018-2024)
Avg $2,139/year across 7 years
Top 11% in CA for pulmonary disease
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
47
Companies
589
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$14,871 (99.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$100 (0.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,863
2023
$2,360
2022
$2,127
2021
$1,948
2020
$1,490
2019
$2,341
2018
$1,842
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$419
Regeneron Healthcare Solutions, Inc.
$349
Mylan Specialty L.P.
$345
Boehringer Ingelheim Pharmaceuticals, Inc.
$318
AstraZeneca Pharmaceuticals LP
$180
Vifor Pharma, Inc.
$174
ABBVIE INC.
$166
Baxter Healthcare
$152
Amgen Inc.
$124
Janssen Pharmaceuticals, Inc
$87
Electromed, Inc.
$73
Grifols USA, LLC
$66
Takeda Pharmaceuticals U.S.A., Inc.
$60
GENZYME CORPORATION
$58
ANI Pharmaceuticals, Inc.
$50
Inari Medical, Inc.
$47
Gilead Sciences, Inc.
$46
United Therapeutics Corporation
$25
Actelion Pharmaceuticals US, Inc.
$25
Seqirus USA Inc
$25
Paratek Pharmaceuticals, Inc.
$23
Pulmonx Corporation
$20
Merck Sharp & Dohme LLC
$18
ZOLL Respicardia, Inc.
$15
Top 3 companies account for 38.9% of 2024 payments
All-time payments by company (2018-2024) ›
Boehringer Ingelheim Pharmaceuticals, Inc.
$3,207
AstraZeneca Pharmaceuticals LP
$2,158
GlaxoSmithKline, LLC.
$2,072
Mylan Specialty L.P.
$1,192
Regeneron Healthcare Solutions, Inc.
$861
Grifols USA, LLC
$843
Takeda Pharmaceuticals U.S.A., Inc.
$699
Amgen Inc.
$362
Genentech USA, Inc.
$350
Baxter Healthcare
$274
Sunovion Pharmaceuticals Inc.
$259
Janssen Pharmaceuticals, Inc
$222
Electromed, Inc.
$196
Philips Electronics North America Corporation
$179
Vifor Pharma, Inc.
$174
ABBVIE INC.
$166
GENZYME CORPORATION
$156
Advanced Respiratory, Inc
$144
Insmed, Inc.
$140
Paratek Pharmaceuticals, Inc.
$116
PFIZER INC.
$112
United Therapeutics Corporation
$89
Teva Pharmaceuticals USA, Inc.
$82
Actelion Pharmaceuticals US, Inc.
$79
Covis Pharma GmBH
$66
Gilead Sciences, Inc.
$61
Merck Sharp & Dohme Corporation
$56
Pulmonx Corporation
$50
ANI Pharmaceuticals, Inc.
$50
Octapharma USA, Inc.
$49
Inari Medical, Inc.
$47
Allergan Inc.
$47
Circassia Pharmaceuticals Inc
$42
Shire North American Group Inc
$41
SANOFI PASTEUR INC.
$39
E.R. Squibb & Sons, L.L.C.
$37
CSL Behring
$35
Merck Sharp & Dohme LLC
$33
Harmony Biosciences LLC
$29
Inspire Medical Systems, Inc.
$27
Seqirus USA Inc
$25
Shionogi Inc
$24
Endogastric Solutions, Inc
$20
ADVANCED RESPIRATORY, INC
$17
Aytu BioScience, Inc
$16
ZOLL Respicardia, Inc.
$15
Sanofi Pasteur Inc.
$14
Top 3 companies account for 49.7% of all-time payments
Associated products mentioned in payments ›
AIRSUPRA · ALVESCO · ANORO · ASMANEX · AVYCAZ · AirDuo Digihaler · Arikayce · BEVESPI AEROSPHERE · BREO · BREO ELLIPTA · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CAPVAXIVE · CHARTIS CATHETER · CUTAQUIG · CUVITRU · DUPIXENT · Dymista · ELIQUIS · ESOPHYX · Esbriet · FARXIGA · FASENRA · FLOWTRIEVER CATHETER · FLUZONE HIGH-DOSE · FLUZONE QUADRIVALENT NORTHERN HEMISPHERE · Fetroja · Fluad · GLASSIA · HYQVIA · Hillrom - Life 2000 Ventilation System · Hillrom - Vest System Model 105 Home Care · Hillrom - Volara System · Hizentra · INSPIRE · LONHALA MAGNAIR · Life 2000 Ventilation System · NUCALA · NUZYRA · Natesto · OFEV · OPSUMIT · OPSUMIT MACITENTAN · PREVNAR 13 · PREVNAR 20 · PROAIR · PURIFIED CORTROPHIN GEL · ProAir Digihaler · Prolastin-C · Prolastin-C Liquid · Pulmonx Endobronchial Valve EBV · QVAR · Respiratoriy Care Undiv · S · S&RC Und · SMARTVEST · SPIRIVA · SPIRIVA RESPIMAT · STIOLTO · STIOLTO RESPIMAT · SYMBICORT · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · The VitalCough System · Trilogy 100 · UPTRAVI · Utibron · Wakix · XARELTO · Xembify · Xolair · YUPELRI · Yupelri · Zemaira · inCourage · remede System
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Pulmonary diseases within 10 mi
116
Per 100K population
3.7
County median income
$113,702
Nearest hospital
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Moricca is a clinical cardiology specialist, with above-average Medicare volume (top 14% in CA), with low-engagement industry engagement in the top 11% of CA peers, with 19 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Moricca experienced with airflow rate measurement test?
Based on Medicare claims data, Dr. Moricca performed 768 airflow rate measurement test services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Moricca receive payments from pharmaceutical companies?
Yes. Dr. Moricca received a total of $14,971 from 47 companies across 589 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Moricca's costs compare to other pulmonary diseases in Newport Beach?
Dr. Moricca's average Medicare payment per service is $55. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Moricca) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Newport Beach
Browse pulmonary diseases in Newport Beach ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in CA
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in CA
Which CA pulmonary diseases receive the most from drug and device companies.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology